NCT04278144: A First-in-human Study Using BDC-1001 in Advanced and HER2-Expressing Solid Tumors

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with prior treatment of a TLR 7, TLR 8 or a TLR 7/8 agonist; Patients with uncontrolled unstable symptomatic brain metastasis- see trial for details

Comments are closed.

Up ↑